The CSL Limited (ASX: CSL) share price is shooting higher again on Thursday.
In afternoon trade, the biotherapeutics company’s shares are up a sizeable 5% to $276.18.
This means the CSL share price is now up an impressive 14% in the space of just two days.
Why is the CSL share price charging higher?
Investors have been bidding the CSL share price higher since the release of its half year results on Wednesday.
For the six months ended 31 December, CSL reported a 5.3% increase in revenue to US$6,041 million but a 5% constant currency decline in net profit after tax to US$1,722 million.
However, getting investors excited was management speaking positively about the outlook for plasma collections and upgrading its full year profit guidance.
The tide is turning
The team at Morgans remains positive on the CSL share price and has put an add rating and $327.60 price target on its shares. This implies potential upside of almost 19% for investors even after its recent gains.
Morgans commented: “CSL – 1H above expectations; the “tide is beginning to turn” 1H results were better than expected, albeit in line with management’s assumptions, with net profit down 5% in cc on 4% revenue growth. Seqirus was the standout on pandemic driven demand for influenza vaccines, while Behring went backwards as plasma-based products were constrained on tight supply and higher costs, although certain Specialty product saw gains.”
“Promisingly, plasma collections continue to improve, although remain slightly below pre-pandemic levels, and while industry wide issues remain (eg Omicron; staffing; increase costs), the worst appears behind us,” it added.
All in all, it may not be too late for investors to pick up CSL shares, according to this top broker.
The post The ‘tide is beginning to turn’: CSL (ASX:CSL) share price tipped to rise appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- CSL (ASX:CSL) share price jumps 8% on guidance upgrade and positive plasma outlook
- Why CSL, Liontown, Nearmap, and Treasury Wine shares are storming higher
- ASX 200 (ASX:XJO) midday update: CSL upgrades guidance, Treasury Wine jumps
- CSL (ASX:CSL) delivers US$1.7bn half year profit and tips plasma collection rebound
- Down by a quarter in less than three months, is the CSL (ASX:CSL) share price a buy?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/huSrFK6
Leave a Reply